LeonaBio Q2 2026 net loss $19.0M; cash $51.1M; ELAINE-3 enrollment on track

LeonaBio, Inc.

Net loss $19.0M ($0.80/sh) vs $7.0M ($1.78/sh) in Q2 2025; R&D spend up to $12.9M from $3.7M.
Cash, equivalents and investments $51.1M at June 30, 2026, down from $88.3M at Dec 31, 2025; ops cash burn $37.9M in quarter.
ELAINE-3 Phase 3 trial enrolled 495 patients; enrollment completion expected Q4 2026, topline data 2H 2027.
Up to $146M potential from cash-exercisable warrants from Dec 2025 financing to support development.
Board additions: Fred Callori, Natalie Holles, Peter Silverman effective May 5, 2026; John Fluke retired May 4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.